Discirculatory encephalopathy: the main targets of therapy


Cite item

Full Text

Abstract

The article presents review of current data for clinical manifestations and pathophysiology of various forms of dyscirculatory encephalopathy (DE). The main goals in the treatment of DE are correction of risk factors, the compensation of chronic cerebral ischemia, and the prevention of recurrent cerebrovascular events. The present article considers the main guidelines in the treatment of DE. It is emphasized that the principal direction in the prevention of ischemic cerebral lesions is antiplatelet therapy. Various options of antiplatelet therapy with acetylsalicylic acid (ASA), clopidogrel, ticlopidine, and dipyridamole are discussed. The advisability of a combination of ASA + dipyridamole is proved. This combination should be used as first-line secondary prevention of ischemic stroke, especially in patients with unstable course of arterial hypertension, predisposition to hypertensive crisis, gastric ulcer and duodenal ulcer, and high risk of bleeding.

About the authors

G R Tabeeva

G Tabeeva

References

  1. Барышникова Г.А. Применение дипиридамола в общетерапевтической практике // Справочник поликлинического врача. 2007. № 14. C. 11-16.
  2. Бурцев Е.М. Вопросы классификации, клинического течения и патогенетического лечения дисциркуляторной энцефалопатии // Журнал невропатол и психиатр им. Корсакова 1991. № 7. С. 19-22.
  3. Варакин Ю.Я., Никитин Ю.М., Жигалко В.К. Поражение магистральных артерий головы // Журн невропатол и психиатр им. Корсакова 1994. № 2. С. 21-24.
  4. Гулевская Т.С., Людковская И.Г. Артериальная гипертония и патология белого вещества мозга // Арх пат. 1992. № 2. С. 33-59.
  5. Дамулин И.В. Сосудистая деменция // Неврологический журнал 1999. № 3. С. 411-416.
  6. Захаров В.В. Сосудистые когнитивные расстройства // РМЖ 2005. № 13(12). С. 2-7.
  7. Кухтевич И.И. Церебральный атеросклероз. М., 1998. 183 с.
  8. Левин О.С. Сосудистый паркинсонизм // Неврологичесий журнал. 1997. № 4. С. 42-51.
  9. Суслина З.А., Танашян М.М., Домашенко М.А. Антитромбоцитарная терапия ишемических нарушений мозгового кровообращения. М., 2009. 222с.
  10. Хорват Ш. Кавинтон в терапии хронической недостаточности мозгового кровообращения // Неврологичесий журнал. 2004. № 9. С. 39-46.
  11. Янакаева Т.А. Эмоционально-аффективные нарушения при дисциркуляторной энцефалопатии и болезни Паркинсона. Дисс. канд. мед. наук. М., 1999.
  12. Яхно Н.Н., Левин О.С., Дамулин И.В. Сопоставление клинических и МРТ-данных при дисциркуляторной энцефалопатии. Сообщение 1: двигательные нарушения // Неврологический журнал. 2001. № 6. С. 10-16.
  13. Яхно Н.Н., Левин О.С., Дамулин И.В. Сопоставление клинических и МРТ-данных при дисциркуляторной энцефалопатии. Сообщение 2: когнитивные нарушения // Неврологический журнал. 2001. № 6. С. 10-19.
  14. Albers GW., Amarenco P., Sacco RL., Teal P. Antithrombotic and thrombolytic therapy for ischemic stroke. Chest 2004;126 (suppl):483-512.
  15. Chabriat H, Bousser MG. Vascular dementia: potential of antiplatelet agents in prevention Eur Neurol 2006;55(2):61-9.
  16. Collaborative meta-analysis of randomized trials of antipatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324:71-86.
  17. De Schryver EL, Algra A, van Gijn J. Dipyridamole for preventing stroke and other vascular events in patients with vascular disease. Cochrane Database Syst Rev 2006;(2):1820.
  18. European Stroke Initiative Executive Committee and the EUSI Writing Committee: European Stroke Initiative recommendations for stroke management - update 2003. Cerebrovasc Dis 2003;16:311-37.
  19. Hachinski VC. Binswanger disease: neither Binswangers nor a disease. J Neur Sci 1991;103;113.
  20. Hachinski VC, Lassen NA, Marshall J. Multiinfarct dementia. A case of mental deterioration in the elderly. Lancet 1974;2:207-10.
  21. Jamieson DG, Parekh A, Ezekowitz MD. Review of antiplatelet therapy in secondary prevention of cerebrovascular events: a need for direct comparisons between antiplatelet agents. J Cardiovasc Pharmacol Ther 2005;10:153-61.
  22. Leonardi-Bee J, Bath PMW, Bousser MG, et al. Dipirydamole fоr prevention recurrent ischemic stroke and other vascular events: a meta-analysis of individual patient data from randomized controlled trials. Stroke 2005;36:162-8.
  23. Ling G, Ovbiagele B. Oral antiplatelet therapy in the secondary prevention of atherothrombotic events. Am J Cardiovasc Drugs 2009;9(3):197-209.
  24. National Institute for Health and Clinical Excellence. Clopidogrel and modified-release dipyridamole in the prevention of occlusive vascular events - guidance. NICE, London, UK, 2004.
  25. PROGRESS Collaborative Group. Randomized trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischemic attack. Lancet 2001;358:1033-41.
  26. Royal College of Physicians: National Clinical guidelines for stroke, 2nd edition. Prepared by the Intercollegiate Stroke Working Party. Royal College of Physicians, London, UK, 2004.
  27. Saccо RL, Sivenius J, Diener CH. Efficacy of aspirin plus extended-release dipyridamole in preventing recurrent stroke in high-risk population. Arch Neurol 2005;62:403-8.
  28. Sudlow C. Dipyridamole with aspirin is better than aspirin alone in preventing vascular events after ischemic stroke or TIA. BMJ 2007;334(7599):900-1.
  29. The ESPRIT Study Group. Aspirin plus dipyridamole versus aspirin alone after cerebral ischemia of arterial origin (ESPRIT). Lancet 2006;367:1665-1673.
  30. Vande Griend JP, Saseen JJ. Combination antiplatelet agents for secondary prevention of ischemic stroke. Pharmacotherapy 2008;28(10):1233-42.
  31. Cambia-Kiely JA, Gandhi PJ. Possible mechanism of aspirin resistance. J Thromb Thrombolysis 2002;13:49-56.
  32. Eikelboom JW, Hirsh J, Weitz JI, et al. Aspirin Resistance Aspirin Resistance Response. Circulation 2002;106:200-1.
  33. Gum PA, Kottke-Marchant K, Welsh PA, et al. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Amer Coll Cardiology 2003;41:961-5.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2010 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies